Introduction Synthetic cannabinoid receptor agonists (SCRAs) are heterogeneous compounds originally intended as probes of the endogenous cannabinoid system or as potential therapeutic agents. We assessed the clinical toxicity associated with recent SCRA use in a large cohort of drug overdose patients. Methods This subgroup analysis of a large (n = 3739) drug overdose cohort study involved consecutive ED patients at two urban teaching hospitals collected between 2009 and 2013. Clinical characteristics of patients with the exposure to SCRAs (SRCA subgroup) were compared with those from patients who smoked traditional cannabinoids (marijuana subgroup). Data included demographics, exposure details, vital signs, mental status, and basic chemistries gathered as part of routine clinical care. Study outcomes included altered mental status and cardiotoxicity. Results Eighty-seven patients reported exposure to any cannabinoid, of whom 17 reported SCRAs (17 cases, 70 controls, mean age 38.9 years, 77 % males, 31 % Hispanic). There were no significant differences between SRCA and marijuana with respect to demographics (age, gender, and race/ethnicity), exposure history (suicidality, misuse, and intent), vital signs, or serum chemistries. Mental status varied between SRCA and marijuana, with agitation significantly more likely in SCRA subgroup (OR = 3.8, CI = 1.2-11.9). Cardiotoxicity was more pronounced in the SCRA subgroup with dysrhythmia significantly more likely (OR = 9.2, CI = 1.0-108). Conclusions In the first clinical study comparing the adverse effects of SCRA overdose vs. marijuana controls in an ED population, we found that SCRA overdoses had significantly pronounced neurotoxicity and cardiotoxicity compared with marijuana.
Introduction
Over the last half century, a new class of recreational drugs has emerged, synthetic cannabinoid receptor agonists (SCRAs). Synthetic cannabinoid receptor agonists are a heterogeneous group of compounds that were originally developed as probes of the endogenous cannabinoid system or as potential therapeutic agents. Unfortunately, clandestine laboratories subsequently synthesized and marketed SCRAs as designer drugs of abuse [1] . Although originally designed in the 1960s as potential therapeutic agents [2] , there has been a rapid increase over the most recent few decades in their recreational use and abuse in large part because of their relatively low cost, ambiguous legality, easy availability, and lack of cross reactivity with established urine drug tests for THC. These synthetic compounds are sprayed over plant material and then packaged and distributed to the public [3] ; they can be inhaled, ingested, or injected [4] .
At present, there is a paucity of research describing the effects of SCRA ingestion. Several case reports, and fewer case series [5, 6] , suggest effects of SCRA ingestion include vomiting, tachycardia, tremor, severe agitation [7] , bradycardia [8] , psychosis [9] , and psychotic relapses [10] . There is even a case report describing tolerance and withdrawal phenomenon for a specific variant SCRA branded product named BSpice Gold^ [11] . One regional Poison Control Center's experience has also been published with respect to poisoning severity and tallying general clinical manifestations [12] . Two recent systematic reviews of available case reports found the most common SCRA effects reported as tachycardia, agitation, and nausea [13, 14] .
Of late, there has been an overwhelming rise in the presentation of fatal SCRA ingestions to Emergency Departments (ED). We believe that there is a pressing need for better documentation and analysis of the toll SCRAs is taking on our patients. We therefore assessed the clinical toxicity associated with recent SCRA use in a large cohort of drug overdose patients. Based on prior literature, we hypothesized significant associations with agitation [13, 14] and cardiotoxicity [7, 8, 13, 14] when compared to marijuana.
Methods
Study Design and Setting This was a subgroup analysis from a larger prospective cohort of consecutive ED adult patients with acute drug overdose at two large urban teaching hospitals collected between 2009 and 2013 [15, 16] . The current study examined the subgroup with self reported exposure to SCRAs (SRCA subgroup) compared with patients with self-reported exposure to regular marijuana (MARIJUANA subgroup). This study was conducted with approval from all involved sites' institutional review boards with waiver of informed consent.
Study Population Patients with suspected drug overdose were screened by trained research assistants for inclusion. Patients were included who met both of the following criteria: (1) acute presentation (within 24 h of exposure) and (2) suspected overdose (i.e., illicit drug dose sufficient to cause symptoms or any prescription drug exposure greater than its therapeutic dose). Exclusion criteria for the present study were the following: alternative diagnosis (e.g., trauma or infection), chronic presentation (i.e., not meeting acute criteria above), exposures limited to dermal means only, age younger than 18 years, anaphylaxis, and prisoners.
Study Protocol Patients were identified by a trained research assistant who rounded during business hours to find acute overdose cases and by cases that were called in to the poison center from either of the participating hospitals. While poison control center data were used for screening and inclusion, all other data, including outcomes, were abstracted from hospital medical records.
Data were collected from the charts by research assistants trained in medical abstraction and recorded using standardized data collection forms. Random sampling of 10 charts with 95 % agreement was done prior to initiation of mass data extraction. Data were abstracted to a de-identified electronic database with password protection.
Subjects were prospectively followed during their hospital stay through to hospital discharge with data that included electronic medical records, paper medical records, and consult records. Results (from electronic physician notes, laboratory records, radiology results, and discharge summaries) were prospectively available to the study investigators.
Data and Measurements Data included demographics (sex, age, and race), exposure details (timing of exposure, number of exposures, intent, and suicidality), toxin identification (detail from history and physical interview, serum drug concentrations if available), toxicology screens (urine ELISA panel and serum concentration, if available), initial ED vital signs, initial ED mental status, initial basic chemistries, and initial electrocardiograms (ECG) gathered as part of the routine clinical care. All patients in the marijuana subgroup had positive urine toxicology (marijuana metabolite THC-COOH).
Study outcomes included altered mental status (agitation, GCS) and cardiotoxicity (myocardial injury, dysrhythmia, and shock), as previously validated [15] . Myocardial injury was defined as any elevation of cardiac troponin I > 0.09 mg/dL. Dysrhythmia was defined as the occurrence of either ventricular tachycardia or fibrillation during the in-hospital stay. Shock was defined as hypotension requiring the administration of vasopressors.
Statistical Analysis Associations between SCRA clinical factors and the study outcomes were calculated using univariate analysis, with marijuana patients as the Bcontrol^group. We calculated 95 % confidence intervals using the estimated standard error method. Chi-squared (with two-tailed Fisher's exact test when appropriate) and Mann-Whitney test were calculated for categorical and continuous variables, respectively, with one degree of freedom and 5 % alpha (two-tailed).
Results
Clinical Characteristics Study enrollment from the original cohort of 3739 patients is summarized in Fig. 1 . The demographics characteristics of the 87 patients who reported exposure to any cannabinoid are outlined in Table 1 . There were no significant differences between groups with respect to demographics or intent of exposure (suicidality, recreational, and misuse).
Based on the initial basic chemistries gathered as part of the routine clinical care, there were no significant differences between SCRA vs. marijuana with respect to any of the following: sodium (139 vs. 140.7, mean difference = −1.7 mEq/L), glucose (138.9 vs. 110.8, mean difference = +28.1 mg/dL), potassium (3.9 vs. 3. 1.02, mean difference = +0.01 mg/dL), or lactate (2.88 vs. 2.44, mean difference = +0.44 mEq/L).
Electrocardiographic data were available for 82 patients (15 SCRA and 67 marijuana). There were no significant associations with SCRA with respect to the following computergenerated parameters: Rate (100.0 vs. 88.6, mean difference = +11.4 bpm), QRS (90.0 vs. 88.4, mean difference = + 1.6 ms), or QTc (448.3 vs. 441.4, mean difference = +6.9 ms).
Main Results Cardiovascular profiles of patients are summarized in Table 2 . There were no differences between groups with respect to initial ED heart rate or blood pressure. Dysrhythmia was significantly associated with SCRA (OR = 9.2, CI = 1.01-108). There was no association between SCRA exposure and myocardial injury.
Neurological profiles of patients are summarized in Table 3 . There were no differences between groups with respect to initial GCS, proportion of altered mental status, coma, or delirium. SCRA exposure was associated with higher rates of agitation (OR = 3.8, CI = 1.2-11.9).
Discussion
This is the first human study comparing the clinical effects of synthetic cannabinoid receptor agonists (SCRAs) vs. marijuana controls in an ED population of acute drug overdose. We found that SCRA overdose was significantly associated with more severe clinical toxicity than marijuana, including neurotoxicity and cardiotoxicity. These results should be used to No substantial/significant differences between groups with respect to demographics, or intent of exposure.
Abbreviations: SCRA synthetic cannabinoid receptor agonist inform treating healthcare providers in attempts to prevent adverse clinical outcomes following SCRA overdoses, especially given that SCRA abuse and overdose will likely become more common in the years to come. Our findings of agitation and cardiac dysrhythmia suggest an atypical sympathomimetic SCRA toxidrome. Interestingly, sympathomimetic effects were previously described in case reports of SCRA ingestion. In two cases published by Schneir et al in 2010, both patients reported feeling Banxiousâ nd one was found to be tachycardic on arrival to the ED [7] . These patients felt the need to activate Emergency Response Services after smoking an SCRA called BBanana Cream Nuke.^It appears what concerned these patients was that they felt disoriented, Bas if [they] didn't know where [they] were.T he authors submitted the packets for analysis and identified compounds JWH-018 and JWH-073. Similarly, case reports from several authors indicate significant variability in the content of these packets; this presents a challenge in studying the clinical effects of SCRAs as a class [17] . Further, it is unclear whether these patients had any underlying mental illness or addiction to other drugs of abuse. Effects of various different SCRA compounds on patients with pre-existing psychiatric comorbidity is even more challenging to study.
Case reports of SCRA use have reported psychiatric presentations including agitation [7] and psychosis [18] , and the present study's association of SCRA use with agitation adds credence to these case report findings. To add complexity to the interpretation of these findings, there are likely many users of SCRAs who have underlying mental illness. A study from New Zealand conducted semi-structured interviews with 15 mentally ill patients who had used and SCRA containing substance called BAroma^ [9] . Results found that 100 % of the sample described psychoactive effects after ingesting Aroma; 69 % reported having psychotic symptoms; 15 % reported feeling anxious. Five patients endorsed symptoms of psychotic relapse within 24 h of smoking Aroma, which lasted anywhere from hours to several weeks. This qualitative study sheds light on an important issue regarding the possibility of novel and deleterious effects of SCRAs on mentally-ill individuals. Further studies of psychiatric effects of SCRA abuse are warranted to determine whether SCRA abuse may cause psychiatric sequelae independent of prior psychiatric medical conditions [19] .
Our findings of cardiotoxicity associated with SCRA use add to a growing body of evidence in this regard. Scattered reports suggest that there is a potential association between traditional cannabis use and cardiotoxicity, as summarized in a recent report from the Euro-DEN group [20] . One possible mechanism of myocardial depression and conduction abnormalities due to cannabinoid receptor agonism includes blockade of Na + channel and inhibition of Na+/Ca2+ exchanger in cardiac myocytes [21] [22] [23] . Many case reports of SCRA toxicity describe patients presenting with tachycardia [24] , and even junctional bradycardia [8] , after SCRA exposure. Young et al. describe a 17-year-old man who presented to the ED with pounding chest pain, pressure, dyspnea on exertion, and hallucinations 10 min after smoking K9 (SCRA) [8] . He endured a lengthy hospital stay with continued chest pain unresponsive to nitroglycerin. This patient, however, had coingested Oxyelite (a diet pill containing caffeine) along with smoking the K9. Thus, it is unclear if the resultant cardiotoxicity was in part due to the combination of the SCRA and the Bdiet pill^. In addition to these reports, other cases have noted myocardial infarction [25] , QT prolongation [26] , and sudden cardiac death [27] following SCRA exposure. Therefore, the associations of the present study with cardiotoxicity are both consistent with, and add to, the current understanding of SCRA-related cardiotoxicity.
This is the first controlled study comparing the clinical effects of SCRAs vs. marijuana in an ED population of acute drug overdose. Questions raised by the current study require subsequent validation, most importantly the association with dysrhythmia. Since the seizure prevalence and non-lethal dysrhythmias (e.g., supraventricular tachycardias) were unanswerable by this study, future studies should address these as well. Finally, future clinical trials investigating the optimal treatment and management regimens for SCRA overdose are warranted.
Limitations This subgroup analysis has some possible limitations, including self-reported SCRA data (i.e., no GCMS confirmation of SCRA), which may represent misclassification bias; however, all patients in the SCRA subgroup had self-reported and clinician-documented exposure to SCRAs; therefore, this is unlikely a true limitation. Furthermore, all patients in the marijuana subgroup had positive urine toxicology screens. Some potential toxicities, most notably seizures and psychosis, could not be assessed given their absence from the original data collection instrument. Because multi-drug exposures were included, effects may be incorrectly ascribed to marijuana or SCRA and may in fact represent effects from other exposures; however, given the biological plausibility of the clinical findings, this also is unlikely a true limitation. It is possible that trained research assistant availability was a limitation for nights and weekends; however, charts were reviewed and screened for the prior night and weekend regularly so this is unlikely a true limitation. And finally, small numbers over a number of years may introduce limitations about the current validity, reliability, and transferability of these data; however, our findings represent an important first controlled study in understanding differences between SCRA and marijuana toxicity.
Conclusions
In the first clinical study comparing the adverse effects of SCRA overdose vs. marijuana controls in an ED population, we found that SCRA overdose was significantly associated with more severe clinical toxicity than marijuana. Adverse effects included significant associations with neurotoxicity and severe cardiotoxicity. Future studies should assess the optimal treatment modalities to prevent adverse clinical outcomes following SCRA overdoses.
